Published: 10th May, 2021
The World Health Organization (WHO) approved the Sinopharm Covid-19 vaccine for emergency use, the first Chinese jab to receive the WHO's green light.
Context
The World Health Organization (WHO) approved the Sinopharm Covid-19 vaccine for emergency use, the first Chinese jab to receive the WHO's green light.
About
About the Sinopharm Covid-19 vaccine
- EUL: WHO gave emergency use listing (EUL) to Sinopharm Beijing's Covid-19 vaccine.
- Safer: It has become the sixth vaccine to receive WHO validation for safety, efficacy and quality.
- Additional support: The Strategic Advisory Group of Experts on Immunisation, or SAGE, has also reviewed the available data, and recommends the vaccine for adults 18 years and older, with a two-dose schedule.
- Institution: The Sinopharm vaccine is produced by the Beijing Bio-Institute of Biological Products Co Ltd, which is a subsidiary of China National Biotec Group (CNBG).
- It is a two-dose vaccine.
- It is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell).
- Its easy storage requirements make it highly suitable for low-resource settings.
- Widespread use:The Sinopharm vaccine is already in use in 42 territories around the world.
- It is fourth most used vaccine behind AstraZeneca (166), Pfizer-BioNTech (94) and Moderna (46).
- Along with China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia and Seychelles, among others.
How the move is significant?
- Accessibility: It opens the door for the jabs to enter in the Covax global vaccine-sharing scheme.
- It aims to provide equitable access to doses around the world and especially in the poorer countries.
- The move would help Beijing to step up its vaccine diplomacy amid the surge in coronavirus vaccines in several countries.
-
|
Emergency Use Listing (EUL)
Vaccines approved under the EUL for Covid-19
|
Courses
Study
Notes
Home
Resources
More
